TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism
Gut. 2024 May 2:gutjnl-2023-331396. doi: 10.1136/gutjnl-2023-331396. Online ahead of print. ABSTRACT OBJECTIVE: Achieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory …